The United States has a paradox at its heart: it is both the best-resourced country in the world for Lyme disease and one of the hardest to navigate. The knowledge exists, the specialists exist, the treatments exist — but reaching them takes money, persistence, and above all understanding. This page maps that landscape honestly, so you can spend your energy wisely rather than expensively.
If you're in the US and already exhausted — by the doctors, the denials, the bills, the sheer effort of trying to get well — that exhaustion is not a personal failing. It's what this system does to people.
But knowledge genuinely shifts the odds here. The more you understand, the less this illness can be used against you.
The US is the epicentre — and it's still growing
Lyme disease is the most common vector-borne disease in the United States and the fastest-growing. The CDC estimates that around 476,000 people are diagnosed and treated for it each year — a figure rising roughly 5% annually — even though only a fraction (tens of thousands) show up in official surveillance, because reporting captures perhaps one case in ten.
Risk is geographically focused: about 90% of cases come from 15 higher-incidence states across the Northeast, mid-Atlantic and upper Midwest, with Maine, Vermont, New Hampshire, Pennsylvania, New York, New Jersey, Connecticut, Wisconsin and Minnesota among the hardest hit. The vector is the blacklegged (deer) tick, Ixodes scapularis in the east and Midwest and Ixodes pacificus on the West Coast. The same ticks increasingly carry co-infections too — Babesia, Anaplasma, and Powassan virus among them.
Enormous options, guarded by three gates
Here is the thing to understand before anything else. The US has Lyme-literate physicians, specialty laboratories, integrative clinics, herbal expertise, and more active research than anywhere. The problem is almost never that help doesn't exist — it's that three gates stand between you and it: cost, insurance rules, and knowledge.
Of the three, knowledge is the one you can seize for yourself, and it quietly unlocks the other two. People who do well in the American system are rarely the wealthiest; they're the ones who understood their own illness, learned how the system actually works, and made deliberate choices instead of drifting wherever the insurance card pointed. That is a learnable skill — and the rest of this page is about it.
IDSA vs ILADS — the divide that shapes everything
Almost every frustration in American Lyme care traces back to a split between two sets of medical guidelines. Knowing both is essential, because it explains why doctors, tests and insurers behave as they do.
The Infectious Diseases Society of America, aligned with the CDC, holds that most Lyme is cured by a short antibiotic course (typically 10–14 days, up to 28 for later stages). Symptoms persisting afterwards are termed Post-Treatment Lyme Disease Syndrome (PTLDS), which it does not regard as ongoing infection, and it advises against long-term antibiotics as unproven and potentially harmful. It acknowledges patients' suffering is real.
The International Lyme and Associated Diseases Society argues that short courses often fail to eradicate the bacteria, that persistent infection and co-infections are real, and that treatment should be individualized and, where needed, longer — at the physician's clinical judgement. Lyme-literate doctors (LLMDs) generally follow this approach.
This isn't a detail — it's the fault line the whole US system runs along. Insurance follows the IDSA standard, so anything beyond it is where patients get stranded. Understanding that both frameworks exist lets you interpret what any given doctor tells you, rather than assuming their view is the only one.
Why treatment isn't covered — and what it can cost
Be prepared for this, because it blindsides people. Because insurers base coverage on the IDSA/CDC standard, treatment for chronic or persistent Lyme is often classed as "experimental" and denied. Most Lyme-literate doctors are therefore out-of-network and don't take insurance, meaning patients pay upfront, in full, for visits, specialty testing, and long-term or IV treatment.
Nearly half of Lyme patients pay over $5,000 out of pocket, and for those with complex chronic illness the total can reach tens — occasionally hundreds — of thousands of dollars; one widely reported patient spent $100,000 over three years. On top of that, many become too sick to work: in one large survey, over 40% had to quit or cut back. None of this is said to frighten you, but to arm you — going in with open eyes is how you protect both your health and your household.
How to navigate it without going broke
This is where knowledge pays for itself. There is almost always a smarter, cheaper path than the obvious one — you just have to know it exists. A few that genuinely help:
Ask any out-of-network LLMD's office for a "super-bill" you can submit to your insurer yourself; you may recover part of your costs, and denials can be appealed. Consider seeing the nurse practitioner or physician assistant within an LLMD practice — they're supervised by the LLMD, can test and prescribe, and usually cost less. Ask whether a knowledgeable primary-care doctor will collaborate or learn, keeping in-network care where possible. Look into financial-assistance foundations — LymeLight (grants for those up to 25), the Lyme Test Access Program (reimbursing much of testing costs), the Lyme Treatment Foundation, Ride Out Lyme and others — and peer-mentor programs that pair you with someone who's walked this road. And tap patient-led knowledge like MyLymeData, where tens of thousands have pooled what worked.
The mindset that matters most is simple: everything here can be learned. The system rewards the resourceful, and resourcefulness is not a talent you're born with — it's a habit you build.
Herbal options for Lyme and co-infections — and the science behind them
One of the most important things to know in America is that some of the most promising, and most affordable, options are botanical — and they're increasingly backed by serious research. Landmark laboratory studies from Johns Hopkins (the Zhang lab) found that several herbs commonly used for Lyme killed Borrelia burgdorferi in the test tube — including its dormant "persister" forms, which standard antibiotics struggle to reach. Cryptolepis sanguinolenta stood out, achieving complete eradication in vitro where doxycycline and cefuroxime did not; Japanese knotweed, Chinese skullcap, black walnut, sweet wormwood and cat's claw also showed strong activity. Follow-up studies found that several of the same herbs — Cryptolepis, Japanese knotweed and Chinese skullcap — are also active against Bartonella and Babesia, two of the most common co-infections.
This is genuinely hopeful, and it's why herbal protocols (Buhner, Cowden, Byron White) are so widely used in the US. But it must be read honestly.
These are laboratory (in vitro) findings — powerful and important, but not the same as proof that the herb cures the disease in a living person; that clinical research is still catching up. And "natural" does not mean gentle: these are potent medicines that can cause significant side effects and interact with prescriptions. Use them as part of a considered plan, ideally with a clinician or medical herbalist who knows their uses and toxicities, and treat them as a serious complement to your care. For the specifics, see the herbal treatment, Buhner protocol, Bartonella and co-infections guides.
Ticks and prevention in the US
Blacklegged ticks are most active in late spring, summer and again in fall, in wooded and brushy areas and tall grass — heavily so across the Northeast and upper Midwest, and along the West Coast for the Pacific species. Removing an attached tick promptly, without squeezing the body, meaningfully lowers the risk of transmission. The CDC publishes regional risk information, and the full prevention toolkit — repellents, permethrin-treated clothing, and tick checks — is in the prevention guide.
American organisations worth knowing
Several are genuinely useful. LymeDisease.org runs MyLymeData, the large patient-led research registry, and strong advocacy. Global Lyme Alliance and the Bay Area Lyme Foundation fund research and offer practical patient resources, including LLMD search tools and peer mentoring. Project Lyme focuses on education and awareness. ILADS (and its education arm) trains and lists Lyme-literate clinicians. For the mainstream framework and risk data, there's the CDC.
I haven't navigated the American system myself, so I won't pretend to know its maze from the inside. But I'll tell you what I believe with my whole heart: in a country with this many options, your most powerful tool isn't money — it's knowledge.
The people who do best here are rarely the richest. They're the ones who learned to think for themselves, to look beyond the insurance card, to understand their own illness well enough to make their own choices. All of that can be learned — and that is the entire reason this site exists.
Frequently asked questions
It's the most common vector-borne disease in the country and the fastest-growing. The CDC estimates around 476,000 people are diagnosed and treated each year and rising, though only tens of thousands appear in official reports — roughly one case in ten. About 90% come from 15 higher-incidence states in the Northeast, mid-Atlantic and upper Midwest.
Insurers base coverage on the IDSA/CDC standard, which is a short antibiotic course. Treatment for chronic or persistent Lyme is often classed as experimental and denied, and most Lyme-literate doctors are out-of-network, so patients frequently pay out of pocket — sometimes tens of thousands of dollars.
They're two competing sets of Lyme treatment guidelines. IDSA (mainstream, CDC-aligned) recommends short antibiotic courses and views lingering symptoms as post-treatment syndrome rather than ongoing infection. ILADS considers persistent infection and co-infections real and supports individualized, often longer treatment. Lyme-literate doctors generally follow ILADS.
Ask for a "super-bill" to submit to your insurer for out-of-network reimbursement and appeal any denials; consider the nurse practitioner or physician assistant in an LLMD practice (often cheaper); ask a primary-care doctor to collaborate; and look into financial-assistance foundations (such as LymeLight and the Lyme Test Access Program) and peer-mentor programs. Herbal and integrative approaches can also be far less expensive.
Johns Hopkins laboratory studies found that several herbs — notably Cryptolepis, Japanese knotweed and Chinese skullcap — can kill Lyme bacteria in the test tube, including the dormant "persister" forms, and some are also active against Bartonella and Babesia. Importantly, this is lab evidence, not proof of cure in people; these herbs are potent, can have side effects and interactions, and are best used under a knowledgeable clinician as part of your care.
Understand the illness itself
Sources & further reading
- US Centers for Disease Control and Prevention (CDC) — Lyme disease data, statistics and surveillance, cdc.gov/lyme
- IDSA / AAN / ACR (2020) and ILADS — the two Lyme disease treatment guidelines
- LymeDisease.org — MyLymeData registry, cost-of-care and clinician-access research, lymedisease.org
- Global Lyme Alliance and Bay Area Lyme Foundation — patient resources, cost of treatment, financial assistance
- Project Lyme — patient education, including herbal-therapy overviews
- Feng, Zhang et al. (Johns Hopkins Bloomberg School of Public Health) — laboratory studies of botanical medicines against B. burgdorferi, Bartonella and Babesia (Frontiers in Medicine, 2020; and related papers)
Last updated: July 2026